Flagship Ventures Fund V, L.P.

CIK 1627639 · last filed 2023-05-26

Flagship Ventures Fund V, L.P. is a corporate insider who has filed 6 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for SANA, was dated Jun 7, 2023. Across all open-market trades the lifetime net is +$38.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $36.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$36.73M

Companies

3

Total Filings

6

Lifetime Open-Market Net

$38.42M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
SANA	10%+ Owner	11,441,326	$3.21	$36.73M	-$14.11M	1	2023-05-26
Rubius Therapeutics, Inc. (RUBY) Delisted	10%+ Owner	5,859,414	$0.08	$486.3K	$42.63M	1	2021-03-23
Codiak BioSciences, Inc. (CDAK) Delisted	10%+ Owner	543,686	$0.06	$31.0K	$9.90M	1	2020-10-20

Recent Filings

6 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2023-06-07	SANA	Notice (144)	−310,170	-$1.98M	EDGAR
2023-05-26	SANA	Sell (S)	−2,180,968	-$14.11M	EDGAR
2023-05-24	SANA	Notice (144/A)	−664,666	-$4.66M	EDGAR
2023-05-24	SANA	Notice (144)	−85,334	-$598.2K	EDGAR
2021-03-23	Rubius Therapeutics, Inc. (RUBY) Delisted	Buy (P)	+1,470,000	$42.63M	EDGAR
2020-10-20	Codiak BioSciences, Inc. (CDAK) Delisted	Mixed	+8,485,416	$9.90M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.